Mark Richards

Beyond Document Delivery: How a Compliance-First CER Strategy Helped Achieve a Successful Notified Body Review

Responsible Integration of Artificial Intelligence in Clinical Evaluation Reports

Navigating the Nagoya Protocol in Pharmaceutical Regulatory Affairs

Companion Diagnostic Studies Under IVDR: Regulatory Requirements, Study Design, and Clinical Evidence Generation

Beyond “Inactive”: Mastering Type IV DMFs for Excipients Using IPEC Guidance

Ethylene Oxide in Pharmaceuticals and Consumer products – Essential Intermediate, High-Risk Exposure – A Regulatory Deep Dive

How to Address Data Consistency Challenges in EU MDR Submissions: A CAPTIS® Perspective

From Supplier to Label: Mastering Allergen Statements in Drugs and Cosmetics